Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,655 across all filing types
Latest filing 2025-06-04 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
关于阿利沙坦酯吲达帕胺缓释片（复立安）获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (984 characters) from Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the receipt of a drug registration certificate for a new pharmaceutical product. It includes details about the drug, its approval by the National Medical Products Administration, and the expected impact on the company's business. There is no financial data, no mention of financial results, no regulatory filings related to financial performance, no shareholder voting, no management changes, no earnings release, and no detailed report attached. The document is clearly an announcement of a regulatory approval event related to the company's product, not a financial or management report. Given the short length and nature of the content, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-06-04 Chinese
关于沙库巴曲阿利沙坦钙片（信超妥）获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shenzhen Salubris Pharmaceuticals Co., Ltd. about receiving a drug registration certificate for a new pharmaceutical product. It includes details about the drug, regulatory approval, and potential impact on company performance. The document is short (972 characters) and serves as a formal announcement of a regulatory approval event rather than a financial report or detailed filing. It does not contain financial statements, management discussion, or detailed regulatory filings like audit reports or annual reports. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-05-27 Chinese
关于获得AGT-siRNA药物GW906独家许可权益的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Shenzhen Xintai Pharmaceutical Co., Ltd. regarding the acquisition of exclusive licensing rights for a drug (AGT-siRNA drug GW906) from Chengdu Guowei Biopharmaceutical Co., Ltd. It details the transaction overview, board approval, licensing terms, payment milestones, risk factors, and other related information. The document is structured as a formal announcement of a capital/financing transaction involving licensing rights and payments, including milestone payments and royalties. It does not contain financial statements, quarterly or annual financial results, or detailed management discussion of financial performance. It is not a report of earnings, annual report, or regulatory filing of financial data. The content fits best under the category of Capital/Financing Update (CAP), as it relates to a significant licensing deal and associated financial commitments by the company.
2025-05-26 Chinese
第六届董事会第十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a board meeting resolution by Shenzhen Salubris Pharmaceuticals Co., Ltd. It details the approval of a licensing agreement for a drug (GW906) and authorizes management to execute related legal documents. The text includes meeting attendance, voting results, and references to supporting documents. It does not contain financial statements or detailed financial performance data. The document is not an annual or interim report, earnings release, or investor presentation. It is a corporate governance announcement related to board decisions and management authorization. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on board resolutions, not a full report or regulatory filing.
2025-05-26 Chinese
关于第二期员工持股计划出售完毕暨终止的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the completion and termination of the company's second employee stock ownership plan. It details the plan's background, stock disposal, compliance with regulations, and future plans. The text is an official company announcement about a specific corporate action related to employee stock plans, not a financial report, earnings release, or regulatory filing. It does not contain financial statements or detailed financial data but rather informs shareholders and the public about the status and conclusion of the employee stock plan. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement that does not fit into more specific categories like capital changes or director dealings.
2025-05-23 Chinese
关于注销部分募集资金专户的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the cancellation of a portion of the special account for raised funds. It details the background of the fundraising, the management of the funds, the decision to close a specific fundraising account, and related regulatory approvals. The document does not contain financial statements or detailed financial data but rather informs about the administrative action related to fundraising accounts and regulatory compliance. The length is about 2281 characters, which is relatively short and focused on a specific corporate action. This fits the category of Capital/Financing Update (CAP), as it relates to the management and changes in the company's fundraising and capital accounts.
2025-05-13 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.